Afon teases its non-invasive blood glucose monitor again while sharing recent crucial steps toward its finger-stick elimination goal

Afon Technology, a medical equipment manufacturing company located in Monmouthshire, Wales, has been teasing its in-the-works non-invasive blood glucose monitor on social media again. Back in March, the firm stated that the launch of its potentially game-changing continuous glucose monitor (CGM) was “coming soon”, although no specific date was posted. This time around, Afon has tweeted “Watch this space” along with two comments that will appeal to diabetics who have to constantly go through the pain of finger-stick measurement:

Imagine not being restricted by your finger stick blood glucose monitor.

Imagine having a device automatically alerting you when your blood sugar levels are going high or low and all that without taking a single drop of blood.

Of course, Afon might be just posting these comments to remind people that it is actually working on a non-invasive blood sugar monitor; however, there are three other pointers that suggest the outfit may be closer to success than some of its many potential rivals. For instance, the firm’s LinkedIn page triumphantly exclaims:

A small team in Wales is on the verge of a major breakthrough in the management of diabetes. Afon Technology has patented a real-time, non-invasive blood glucose monitor with the aim of benefiting millions of diabetes sufferers the world over.

But what might be more pertinent to those millions of diabetics who would love to see the end of painful finger-sticking days are two other recent posts Afon has made in regard to its progress. One describes how the firm has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for a clinical trial in conjunction with Swansea University Hospital. The other tweet details how the company passed a British Standards Institution (BSI) audit as part of a step in getting a vital ISO 13485 certification.

The ISO 13485 standard covers medical devices, so adding this further detail on top of Afon’s teasers and the greenlit clinical trial all points to the non-invasive continuous glucose monitor arriving sooner rather than later. The Afon device is a portable-sized sensor that can be worn as a wearable in its own right or as part of a device such as a smartwatch. Apparently, the monitor uses high-frequency microwaves to estimate glucose levels. There has been a report that stated there were hopes that the Afon non-invasive blood glucose monitor could be available by the end of 2022.

Buy Medline Sterile Safety Lancets on Amazon